EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical Characterization of Pharmacologic NAD + Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis

Carlos Perez-Sanchez iD, Alejandro Escudero-Contreras, Tomás Cerdó, Luz Marina Sánchez-Mendoza, Adrián Llamas-Urbano, Iván Arias-de la Rosa, Miguel Pérez-Rodriguez, Laura Muñoz-Barrera, María Del Carmen Abalos-Aguilera, Nuria Barbarroja iD, Jerusalem Calvo, Rafaela Ortega-Castro iD und 7 weitere

Arthritis & Rheumatology · 2023

DOI: 10.1002/art.42528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2023. Verfasst von Carlos Perez-Sanchez und 18 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, and De…. Hauptthemen laut MEDLINE: NAD, Arthritis, Rheumatoid. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We analyzed NAD + metabolism in patients with rheumatoid arthritis (RA), its association with disease activity and clinical outcomes of RA, and the therapeutic potential of pharmacologic NAD + boosting.

Methods

Our study included 253 participants. In the first cohort, comprising 153 RA patients and 56 healthy donors, we assessed NAD + levels and NAD + ‐related gene pathways. We analyzed 92 inflammatory molecules by proximity extension assay. In the second cohort, comprising 44 RA patients starting anti–tumor necrosis factor (anti‐TNF) drugs, we evaluated changes in NAD + levels and their association with clinical response after 3 months. Mechanistic studies were performed ex vivo on peripheral blood mononuclear cells (PBMCs) from patients with RA to test the beneficial effects of NAD + boosters, such as nicotinamide and nicotinamide riboside.

Results

Reduced NAD + levels were found in RA samples, in line with altered activity and expression of genes involved in NAD + consumption (sirtuins, poly[ADP‐ribose] polymerase, CD38), transport (connexin 43), and biosynthesis (NAMPT, NMNATs). Unsupervised clustering analysis identified a group of RA patients with the highest inflammatory profile, the lowest NAD + levels, and the highest disease activity (as shown by the Disease Activity Score in 28 joints). NAD + levels were modulated by anti‐TNF therapy in parallel with the clinical response. In vitro studies using PBMCs from RA patients showed that nicotinamide riboside and nicotinamide increased NAD + levels via NAMPT and NMNAT and reduced their prooxidative, proapoptotic, and proinflammatory status.

Conclusion

RA patients display altered NAD + metabolism, directly linked to their inflammatory and disease activity status, which was reverted by anti‐TNF therapy. The preclinical beneficial effects of NAD + boosters, as shown in leukocytes from RA patients, along with their proven clinical safety, might pave the way for the development of clinical trials using these compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NADArthritis, RheumatoidHumansLeukocytes, MononuclearTumor Necrosis Factor InhibitorsNiacinamidePoly(ADP-ribose) Polymerases

Substanzen

NADTumor Necrosis Factor InhibitorsNiacinamidePoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, and Department of Cell Biology, Immunology and Physiology, Agrifood Campus o…
  • Rheumatology Service, IMIBIC, Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.
  • Department of Cell Biology, Immunology and Physiology, Agrifood Campus of International Excellence, University of Córdoba, ceiA3, Córdoba, Spain.
  • Department of Cell Biology, Immunology and Physiology, Agrifood Campus of International Excellence, University of Córdoba, and Laboratory GE-06, IMIBIC, Nephrology Service, Reina Sofia University Hospital, ceiA3, Córdob…

ORCID-Profile: Carlos Perez-Sanchez, Nuria Barbarroja, Rafaela Ortega-Castro, Chary Lopez-Pedrera

Zitieren

APA

Perez-Sanchez, C., Escudero-Contreras, A., Cerdó, T., Sánchez-Mendoza, L. M., Llamas-Urbano, A., la Rosa, I. A., Pérez-Rodriguez, M., Muñoz-Barrera, L., Del Carmen Abalos-Aguilera, M., Barbarroja, N., Calvo, J., Ortega-Castro, R., Ruiz-Vilchez, D., Moreno, J. A., Burón, M. I., González-Reyes, J. A., Collantes-Estevez, E., Lopez-Pedrera, C., & Villalba, J. M. (2023). Preclinical Characterization of Pharmacologic NAD + Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.42528

Vancouver

Perez-Sanchez C, Escudero-Contreras A, Cerdó T, Sánchez-Mendoza LM, Llamas-Urbano A, la Rosa IA, et al. Preclinical Characterization of Pharmacologic NAD + Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis. Arthritis & Rheumatology. 2023. doi:10.1002/art.42528

BibTeX
@article{PerezSanchez2023,
  author = {Perez-Sanchez, Carlos and Escudero-Contreras, Alejandro and Cerdó, Tomás and Sánchez-Mendoza, Luz Marina and Llamas-Urbano, Adrián and la Rosa, Iván Arias-de and Pérez-Rodriguez, Miguel and Muñoz-Barrera, Laura and Del Carmen Abalos-Aguilera, María and Barbarroja, Nuria and Calvo, Jerusalem and Ortega-Castro, Rafaela and Ruiz-Vilchez, Desiree and Moreno, Juan Antonio and Burón, María Isabel and González-Reyes, José Antonio and Collantes-Estevez, Eduardo and Lopez-Pedrera, Chary and Villalba, José Manuel},
  title = {Preclinical Characterization of Pharmacologic NAD + Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  doi = {10.1002/art.42528}
}
Kostenlos starten →